Clinical Trials

According to a report from Brightfield Group, the global cannabis market is currently valued at about USD 7.7 Billion and is projected to reach USD 31.4 Billion by 2021. The United States accounts for about 90 percent of the whole market, but its domination of the industry is anticipated to decline to approximately 57 percent […]

Editorial: Lyn Chesna, Managing EditorAdvertising: Maureen Dwyer Liberti, Vice President, Group PublisherGreg Pessagno, National Account ManagerKim Kleinberg, National Account ManagerProduction: Dawn Flook, Director of Production ServicesCirculation: Jackie Ott, Circulation ManagerWebmaster: Webmaster … read more at: https://www.ptcommunity.com/wire/gw-pharmaceuticals-present-goldman-sachs-39th-annual-global-healthcare-conference

LONDON and CARLSBAD, Calif., June 06, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June […]

WEDNESDAY, May 16, 2018 (HealthDay News) — Less appears to be more when it comes to treating epilepsy with the marijuana extract cannabidiol, a new clinical trial suggests. … read more at: http://www.philly.com/philly/health/topics/HealthDay733982_20180516_Low_Dose_of_CBD_Liquid_Eases_Epilepsy_Seizures__Study.html

The daily administration of high CBD, low THC extracts is safe and effective in treating symptoms related to pediatric movement disorders, according to clinical trial data published in the Journal of Child Neurology. Israeli researchers assessed the adjunctive use of CBD extracts in 20 patients with moderate to severe complex motor disorders over a period of five months. […]

WEDNESDAY, May 16, 2018 (HealthDay News) — Less appears to be more when it comes to treating epilepsy with the marijuana extract cannabidiol, a new clinical trial suggests. Patients taking a 10-milligram (mg) daily dose of pharmaceutical grade cannabidiol (CBD) experienced nearly as great a reduction in seizures as patients on 20 mg, and with […]

Tilray Canada has launched its newest product, Tilray 2:100, a formulation of therapeutic cannabis oil containing a high concentration of cannabidiol (CBD), which may help treat Canadian patients with conditions like Dravet syndrome. “We are excited to offer this highly concentrated CBD product to patients in Canada. We developed this product around a strong existing evidence […]

Recently, INSYS Therapeutics, Inc. INSY , a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently initiated a Phase 2 clinical trial of its cannabidiol (CBD) oral solution for evaluation of safety and efficacy in pediatric patients with Prader-Willi syndrome, a rare genetic disease characterized by insatiable appetite in children that […]